Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

NCT05800964 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05800964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05800964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
June 13, 2023
Completion date
January 22, 2026
Enrollment
37 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors